Clinical Trial Update: Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and immunogenicity of long-term GNR-069 therapy in immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• GNR-069 therapy (GNR-069)

Snippet

Sponsor: AO GENERIUM | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED